相似文献
1
Virtual screening of approved clinic drugs with main protease (3CL) reveals potential inhibitory effects on SARS-CoV-2.
J Biomol Struct Dyn. 2022 Feb;40(2):685-695. doi: 10.1080/07391102.2020.1817786. Epub 2020 Sep 10.
2
Finding potent inhibitors for COVID-19 main protease (M): an approach using SARS-CoV-3CL protease inhibitors for combating CORONA.
J Biomol Struct Dyn. 2022 Mar;40(4):1534-1545. doi: 10.1080/07391102.2020.1829501. Epub 2020 Oct 8.
3
Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CL.
J Biomol Struct Dyn. 2021 Aug;39(13):4936-4948. doi: 10.1080/07391102.2020.1782768. Epub 2020 Jun 24.
4
Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL).
J Biomol Struct Dyn. 2021 Sep;39(15):5735-5755. doi: 10.1080/07391102.2020.1792344. Epub 2020 Jul 17.
5
Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 integrated computational approach.
J Biomol Struct Dyn. 2021 Apr;39(7):2607-2616. doi: 10.1080/07391102.2020.1751298. Epub 2020 Apr 13.
6
Computational discovery of small drug-like compounds as potential inhibitors of SARS-CoV-2 main protease.
J Biomol Struct Dyn. 2021 Sep;39(15):5779-5791. doi: 10.1080/07391102.2020.1792989. Epub 2020 Jul 14.
7
Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL): an screening of alkaloids and terpenoids from African medicinal plants.
J Biomol Struct Dyn. 2021 Jun;39(9):3396-3408. doi: 10.1080/07391102.2020.1764868. Epub 2020 May 18.
8
Proposing a fungal metabolite-flaviolin as a potential inhibitor of 3CL of novel coronavirus SARS-CoV-2 identified using docking and molecular dynamics.
J Biomol Struct Dyn. 2022 Jan;40(1):348-360. doi: 10.1080/07391102.2020.1813202. Epub 2020 Sep 2.
9
Identifying the natural compound Catechin from tropical mangrove plants as a potential lead candidate against 3CL from SARS-CoV-2: An integrated approach.
J Biomol Struct Dyn. 2022;40(24):13392-13411. doi: 10.1080/07391102.2021.1988710. Epub 2021 Oct 13.
10
Combined drug repurposing and virtual screening strategies with molecular dynamics simulation identified potent inhibitors for SARS-CoV-2 main protease (3CLpro).
J Biomol Struct Dyn. 2021 Aug;39(13):4659-4670. doi: 10.1080/07391102.2020.1779128. Epub 2020 Jun 18.
引用本文的文献
1
FDA-approved drug repurposing screen identifies inhibitors of SARS-CoV-2 pseudovirus entry.
Front Pharmacol. 2025 Mar 17;16:1537912. doi: 10.3389/fphar.2025.1537912. eCollection 2025.
2
The Identification of Peptide Inhibitors of the Coronavirus 3CL Protease from a L. Hydroalcoholic Extract Using a Ligand-Fishing Strategy.
Mar Drugs. 2024 May 27;22(6):244. doi: 10.3390/md22060244.
3
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
4
In silico identification of 1,2,4-triazoles as potential Candida Albicans inhibitors using 3D-QSAR, molecular docking, molecular dynamics simulations, and ADMET profiling.
Mol Divers. 2023 Oct;27(5):2111-2132. doi: 10.1007/s11030-022-10546-x. Epub 2022 Oct 14.
5
Virtual screening of substances used in the treatment of SARS-CoV-2 infection and analysis of compounds with known action on structurally similar proteins from other viruses.
Biomed Pharmacother. 2022 Sep;153:113432. doi: 10.1016/j.biopha.2022.113432. Epub 2022 Jul 18.
6
Saquinavir: From HIV to COVID-19 and Cancer Treatment.
Biomolecules. 2022 Jul 5;12(7):944. doi: 10.3390/biom12070944.
7
Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2.
Chem Rev. 2022 Jul 13;122(13):11287-11368. doi: 10.1021/acs.chemrev.1c00965. Epub 2022 May 20.
8
A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors.
Antiviral Res. 2022 May;201:105272. doi: 10.1016/j.antiviral.2022.105272. Epub 2022 Mar 9.
9
A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors.
bioRxiv. 2021 Dec 21:2021.12.18.473303. doi: 10.1101/2021.12.18.473303.
10
Hybrid Approach Reveals Novel Inhibitors of Multiple SARS-CoV-2 Variants.
ACS Pharmacol Transl Sci. 2021 Sep 17;4(5):1675-1688. doi: 10.1021/acsptsci.1c00176. eCollection 2021 Oct 8.
Zotero 插件